Allogene Therapeutics, Inc. (ALLO) vs Immix Biopharma, Inc. (IMMX)
A side-by-side comparison of Allogene Therapeutics, Inc. and Immix Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALLO
Allogene Therapeutics, Inc.
$1.49HealthcareDelayed quote: Oct 6, 2026, 9:40 AM EDT
IMMX
Immix Biopharma, Inc.
$9.94HealthcareDelayed quote: Oct 6, 2026, 9:40 AM EDT
Total return — ALLO vs IMMX
growth of $100 · dividends reinvested · last 5yALLO -89.9% (-36.7%/yr)IMMX +176.0% (+22.5%/yr)IMMX compounded faster over this window
Log scale — wide-divergence pair
ALLO IMMX
ALLO vs IMMX: by the numbers
- •IMMX is the larger company ($541M vs $513M market cap).
- •Both run net losses; IMMX's is the smaller (0.00% vs -3566.68% net margin).
Metrics side by side
Valuation
| Metric | ALLO | IMMX |
|---|---|---|
| P/S ratio | 110.46 | N/A |
| P/B ratio | 1.18 | 2.36 |
Profitability
| Metric | ALLO | IMMX |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | -3566.68% | 0.00% |
| ROE | -37.94% | -17.44% |
| ROIC | -34.79% | -18.20% |
Growth (annualized)
| Metric | ALLO | IMMX |
|---|---|---|
| Revenue CAGR (5Y) | -34.47% | N/A |
| Total return CAGR (5Y) | -42.72% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.